EP
VNDA icon

Elkfork Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Elkfork Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$127K Buy
9,548
+448
+5% +$6.24K ﹤0.01% 914
2019
Q2 		$128K Buy
9,100
+252
+3% +$4.01K ﹤0.01% 901
2019
Q1 		$163K Hold
8,848
– – ﹤0.01% 839
2018
Q4 		$231K Buy
+8,848
New +$208K 0.01% 727

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Elkfork Partners's VNDA Position: Q3 2019 in Review

Elkfork Partners increased its Vanda Pharmaceuticals (VNDA) stake by 4.9% in Q3 2019, buying an estimated $6.24K and bringing the position to 9,548 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #914.

Elkfork Partners first reported a position in VNDA in Q4 2018 and has held it in 4 quarters since. The position peaked at $231K in Q4 2018. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Elkfork Partners held 9,548 shares of Vanda Pharmaceuticals worth $127K as of Q3 2019.
  • Elkfork Partners bought 448 Vanda Pharmaceuticals shares in Q3 2019, an estimated $6.24K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #914 holding.
  • Elkfork Partners first reported a position in Vanda Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Elkfork Partners's Vanda Pharmaceuticals position peaked at $231K in Q4 2018.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.